In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates

Table 2 MIC profile of AMK and comparators for isolates of E. coli and K. pneumoniae

Isolates	Antimicrobial agent	Range	Modal	MIC₅₀	MIC₉₀	%S
All isolates	AMK	≤0.5–>128	2	4	16	96
n = 1646	ATM	≤0.06–>64	0.06	0.125	32	85
	FEP	≤0.06–>64	0.06	0.06	32	87
	CAZ	≤0.06–>64	0.25	0.25	64	85
	C/T	≤0.06–>64	0.25	0.25	1	94
	CRO	≤0.06–>64	0.06	0.06	128	84
	CIP	≤0.015–>16	0.015	0.06	32	74
	IPM	≤0.06–>64	0.25	0.25	1	96
	MEM	≤0.06–>64	0.06	0.06	0.06	96
	TZP	≤0.25–>256	2	4	32	88
	TOB	≤0.06–>64	0.5	1	16	84
ESBL+isolates	AMK	0.5–>128	16	8	32	87
n = 173	ATM	≤0.06–>64	64	64	128	9
	FEP	≤0.06–>64	128	128	128	16
	CAZ	0.125–>64	128	64	128	14
	C/T	≤0.06–>64	0.5	1	8	79
	CRO	≤0.06–>64	128	128	128	5
	CIP	≤0.015–>16	32	32	32	16
	IPM	0.125–>64	0.25	0.25	1	94
	MEM	≤0.06–>64	0.06	0.06	0.125	95
	TZP	0.25–>256	4	8	256	62
	TOB	0.25–>64	32	16	64	39
FEP-R isolates	AMK	0.5–>64	8	8	64	79
n = 216	ATM	0.125–>64	128	64	128	6
	FEP	4–>64	128	128	128	0
	CAZ	0.5–>64	128	128	128	9
	C/T	0.125–>64	0.5	1	128	59
	CRO	≤0.06–>64	128	128	128	5
	CIP	≤0.015–>16	32	32	32	13
	IPM	0.06–>64	0.25	0.25	32	75
	MEM	≤0.06–>64	0.06	0.06	32	75
	TZP	0.25–>256	512	32	512	46
	TOB	0.25–>64	32	16	64	32
TZP-R isolates	AMK	0.5–>64	16	8	64	78
n = 191	ATM	≤0.06–>64	128	32	128	36
	FEP	≤0.06–>64	128	16	128	39
	CAZ	0.25–>64	128	64	128	33
	C/T	≤0.06–>64	128	1	128	56
	CRO	≤0.06–>64	128	128	128	35
	CIP	≤0.015–>16	32	32	32	34
	IPM	0.125–>64	0.25	0.5	32	70
	MEM	≤0.06–>64	0.06	0.06	32	71
	TZP	32–>256	512	256	512	0
	TOB	0.025–>64	32	16	64	39

AMK amikacin; ATM aztreonam; FEP cefepime; CAZ ceftazidime; C/T ceftolozane/tazobactam; CRO ceftriaxone, CIP ciprofloxacin; IPM imipenem; MEM meropenem; TZP piperacillin/tazobactam; TOB tobramycin

ISSN: 1476-0711